Comparing guidelines for the treatment of inflammatory bowel disease

Stephen B. Hanauer; Joseph B. Kirsner

doi:10.1159/000354695

Comparing guidelines for the treatment of inflammatory bowel disease

Stephen B. Hanauer, Joseph B. Kirsner

Medicine, Gastroenterology Division

Research output: Contribution to journal › Article › peer-review

Abstract

As we enter into the era of 'personalized medicine', many of the recommendations of 'evidence-based medicine' require scrutiny and adaptation to optimize individual outcomes. Several examples of these discrepancies are exemplified by the topics of aminosalicylate use in Crohn's disease, early use of biologic agents that target TNF and the role of calcineurin inhibitors versus anti-TNF agents in steroid-refractory ulcerative colitis.

Original language	English (US)
Pages (from-to)	360-362
Number of pages	3
Journal	Digestive Diseases
Volume	31
Issue number	3-4
DOIs	https://doi.org/10.1159/000354695
State	Published - Nov 2013

ASJC Scopus subject areas

Gastroenterology

Access to Document

10.1159/000354695

Cite this

@article{e219025ce134467b8a3c9e5bc868e253,

title = "Comparing guidelines for the treatment of inflammatory bowel disease",

abstract = "As we enter into the era of 'personalized medicine', many of the recommendations of 'evidence-based medicine' require scrutiny and adaptation to optimize individual outcomes. Several examples of these discrepancies are exemplified by the topics of aminosalicylate use in Crohn's disease, early use of biologic agents that target TNF and the role of calcineurin inhibitors versus anti-TNF agents in steroid-refractory ulcerative colitis.",

author = "Hanauer, {Stephen B.} and Kirsner, {Joseph B.}",

year = "2013",

month = nov,

doi = "10.1159/000354695",

language = "English (US)",

volume = "31",

pages = "360--362",

journal = "Digestive Diseases",

issn = "0257-2753",

publisher = "S. Karger AG",

number = "3-4",

}

TY - JOUR

T1 - Comparing guidelines for the treatment of inflammatory bowel disease

AU - Hanauer, Stephen B.

AU - Kirsner, Joseph B.

PY - 2013/11

Y1 - 2013/11

N2 - As we enter into the era of 'personalized medicine', many of the recommendations of 'evidence-based medicine' require scrutiny and adaptation to optimize individual outcomes. Several examples of these discrepancies are exemplified by the topics of aminosalicylate use in Crohn's disease, early use of biologic agents that target TNF and the role of calcineurin inhibitors versus anti-TNF agents in steroid-refractory ulcerative colitis.

AB - As we enter into the era of 'personalized medicine', many of the recommendations of 'evidence-based medicine' require scrutiny and adaptation to optimize individual outcomes. Several examples of these discrepancies are exemplified by the topics of aminosalicylate use in Crohn's disease, early use of biologic agents that target TNF and the role of calcineurin inhibitors versus anti-TNF agents in steroid-refractory ulcerative colitis.

UR - http://www.scopus.com/inward/record.url?scp=84888220654&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888220654&partnerID=8YFLogxK

U2 - 10.1159/000354695

DO - 10.1159/000354695

M3 - Article

C2 - 24246988

AN - SCOPUS:84888220654

SN - 0257-2753

VL - 31

SP - 360

EP - 362

JO - Digestive Diseases

JF - Digestive Diseases

IS - 3-4

ER -

Comparing guidelines for the treatment of inflammatory bowel disease

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this